256 related articles for article (PubMed ID: 10383911)
41. Gene- and tissue-specificity of mutation in Big Blue rats treated with the hepatocarcinogen N-hydroxy-2-acetylaminofluorene.
Chen T; Mittelstaedt RA; Shelton SD; Dass SB; Manjanatha MG; Casciano DA; Heflich RH
Environ Mol Mutagen; 2001; 37(3):203-14. PubMed ID: 11317338
[TBL] [Abstract][Full Text] [Related]
42. Intralaboratory optimization and standardization of mutant screening conditions used for a lambda/lacI transgenic mouse mutagenesis assay (I).
Rogers BJ; Provost GS; Young RR; Putman DL; Short JM
Mutat Res; 1995 Mar; 327(1-2):57-66. PubMed ID: 7870099
[TBL] [Abstract][Full Text] [Related]
43. Mutant frequency and molecular analysis of in vivo lacI mutations in the bone marrow of Big Blue rats treated with 7, 12-dimethylbenz[a]anthracene.
Shelton SD; Cherry V; Manjanatha MG
Environ Mol Mutagen; 2000; 36(3):235-42. PubMed ID: 11044905
[TBL] [Abstract][Full Text] [Related]
44. Transmission of mutations in the lacI transgene to the offspring of ENU-treated Big Blue male mice.
Barnett LB; Tyl RW; Shane BS; Shelby MD; Lewis SE
Environ Mol Mutagen; 2002; 40(4):251-7. PubMed ID: 12489115
[TBL] [Abstract][Full Text] [Related]
45. Spontaneous mutation of the lacI transgene in rodents: absence of species, strain, and insertion-site influence.
Zhang S; Glickman BW; de Boer JG
Environ Mol Mutagen; 2001; 37(2):141-6. PubMed ID: 11246220
[TBL] [Abstract][Full Text] [Related]
46. The mutational specificity of 1-nitroso-6-nitropyrene in the lacI gene of Escherichia coli strains deficient in nucleotide excision repair.
Lambert IB; Carroll C; Laycock N; Duval L; Whiteway J; Lawford I; Turner G; Booth R; Douville S; Nokhbeh MR
Mutagenesis; 1998 Jan; 13(1):9-18. PubMed ID: 9491388
[TBL] [Abstract][Full Text] [Related]
47. The butadiene metabolite, 1,2:3,4-diepoxybutane, induces micronuclei but is only weakly mutagenic at lacI in the Big Blue Rat2 lacI transgenic cell line.
Saranko CJ; Recio L
Environ Mol Mutagen; 1998; 31(1):32-40. PubMed ID: 9464313
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the types of mutations induced by 7,12-dimethylbenz[a]anthracene in the lacI and hprt genes of Big Blue rats.
Mittelstaedt RA; Manjanatha MG; Shelton SD; Lyn-Cook LE; Chen JB; Aidoo A; Casciano DA; Heflich RH
Environ Mol Mutagen; 1998; 31(2):149-56. PubMed ID: 9544192
[TBL] [Abstract][Full Text] [Related]
49. Differential in vivo mutagenicity of the carcinogen/non-carcinogen pair 2,4- and 2,6-diaminotoluene.
Hayward JJ; Shane BS; Tindall KR; Cunningham ML
Carcinogenesis; 1995 Oct; 16(10):2429-33. PubMed ID: 7586147
[TBL] [Abstract][Full Text] [Related]
50. Comparison of in vivo mutagenesis in the endogenous Hprt gene and the lacI transgene of Big Blue(R) rats treated with 7, 12-dimethylbenz[a]anthracene.
Manjanatha MG; Shelton SD; Aidoo A; Lyn-Cook LE; Casciano DA
Mutat Res; 1998 Jun; 401(1-2):165-78. PubMed ID: 9639698
[TBL] [Abstract][Full Text] [Related]
51. Mutational spectrum of dimethylnitrosamine in the liver of 3- and 6-week-old lacI transgenic mice.
de Boer JG; Mirsalis JC; Glickman BW
Environ Mol Mutagen; 1999; 34(2-3):80-3. PubMed ID: 10529729
[TBL] [Abstract][Full Text] [Related]
52. Mutation spectrum of 4-nitroquinoline N-oxide in the lacI transgenic Big Blue Rat2 cell line.
Ryu J; Youn J; Kim Y; Kwon O; Song Y; Kim H; Cho K; Chang I
Mutat Res; 1999 Sep; 445(1):127-35. PubMed ID: 10521698
[TBL] [Abstract][Full Text] [Related]
53. Increased mutant frequency and altered mutation spectrum of the lacI transgene in Wilson disease rats with hepatitis.
Sone H; Li YJ; Ishizuka M; Aoki Y; Nagao M
Cancer Res; 2000 Sep; 60(18):5080-6. PubMed ID: 11016632
[TBL] [Abstract][Full Text] [Related]
54. Induction of lacI mutations in Big Blue rats treated with tamoxifen and alpha-hydroxytamoxifen.
Gamboa da Costa G; Manjanatha MG; Marques MM; Beland FA
Cancer Lett; 2002 Feb; 176(1):37-45. PubMed ID: 11790452
[TBL] [Abstract][Full Text] [Related]
55. A selectable system for mutation detection in the Big Blue lacI transgenic mouse system: what happens to the mutational spectra over time.
Knöll A; Jacobson DP; Nishino H; Kretz PL; Short JM; Sommer SS
Mutat Res; 1996 Jun; 352(1-2):9-22. PubMed ID: 8676922
[TBL] [Abstract][Full Text] [Related]
56. Subchronic administration of phenobarbital alters the mutation spectrum of lacI in the livers of Big Blue transgenic mice.
Shane BS; Smith-Dunn DL; deBoer JG; Glickman BW; Cunningham ML
Mutat Res; 2000 Mar; 448(1):69-80. PubMed ID: 10751624
[TBL] [Abstract][Full Text] [Related]
57. Through a glass, darkly: reflections of mutation from lacI transgenic mice.
Stuart GR; Glickman BW
Genetics; 2000 Jul; 155(3):1359-67. PubMed ID: 10880494
[TBL] [Abstract][Full Text] [Related]
58. Tissue-specific mutational spectra of 2-amino-3,4-dimethylimidazo[4,5-f]quinoline in the liver and bone marrow of lacI transgenic mice.
Ushijima T; Hosoya Y; Ochiai M; Kushida H; Wakabayashi K; Suzuki T; Hayashi M; Sofuni T; Sugimura T; Nagao M
Carcinogenesis; 1994 Dec; 15(12):2805-9. PubMed ID: 8001238
[TBL] [Abstract][Full Text] [Related]
59. Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice.
Kohler SW; Provost GS; Fieck A; Kretz PL; Bullock WO; Sorge JA; Putman DL; Short JM
Proc Natl Acad Sci U S A; 1991 Sep; 88(18):7958-62. PubMed ID: 1832771
[TBL] [Abstract][Full Text] [Related]
60. Mutational analysis of the liver, colon and kidney of Big Blue rats treated with 2-amino-3-methylimidazo[4,5-f]quinoline.
Bol SA; Horlbeck J; Markovic J; de Boer JG; Turesky RJ; Constable A
Carcinogenesis; 2000 Jan; 21(1):1-6. PubMed ID: 10607726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
